A clinical trial of Leronlimab in the patients with metastatic triple-negative breast cancer
Phase of Trial: Phase I/II
Latest Information Update: 25 Jan 2019
At a glance
- Drugs Leronlimab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Jan 2019 According to a CytoDyn media release, the company will present details of BLA submission of leronlimab and about this trial during Noble Capital Markets 15th annual NobleCon Investor Conference on January 28, 2019 at 4:30 p.m. ET.
- 07 Jan 2019 Status changed from planning to recruiting, according to a CytoDyn media release.
- 07 Jan 2019 According to a CytoDyn media release, based on the approval from FDA, the company has initiated this study.